Lupin has launched Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Clobetasol Propionate Ointment USP 0.05% had annual sales of around $93.4 million in the US (IQVIA MAT June 2018).
The company’s Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.’s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.